Cite
HARVARD Citation
Oliver, R. et al. (2022). Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study. British journal of dermatology. pp. 652-663. [Online].